Zevra Therapeutics, Inc. ZVRA Remainder of Fiscal Year 2024

Remainder of Fiscal Year 2024 at other companies

ANI PharmaceuticalsANIP

——

BridgeBio PharmaBBIO

——

Mirum Pharmaceuticals, Inc.MIRM

——

BioCryst PharmaceuticalsBCRX

——

Other financials

Income statement

See full

Revenue$36.2M+77.5%

Gross profit$34.3M+80.1%

Operating income$52.1M+1,073%

Net income$37.9M+1,323%

EPS (diluted)$0.60+1,100%

Balance sheet

See full

Cash & equivalents$95.6M+156%

Total debt$1.1M-98.1%

Total equity$205.8M+402%

Total assets$278.6M+61.3%

Cash flow

See full

Operating cash flow$6.1M+175%

CapEx$35.0K-64.6%

Free cash flow$6.1M+173%

Valuation

See full

Market cap$782.09M+58.2%

Enterprise value$687.64M+32.5%

P/E6.3×—

P/S6.4×-5.8×

Profitability

See full

Gross margin86.1%+7.2pp

Operating margin-103.9%-43.0pp

Net margin101.6%+60.1pp

FCF margin-75%-30.5pp

Returns & leverage

See full

Return on equity100.7%+60.3pp

Debt / equity0×-1.5×

Current ratio4.9×+1.9×

Where this comes from

Reported directly by Zevra Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear.

The official record: Zevra Therapeutics, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Zevra Therapeutics, Inc.'s remainder of fiscal year 2024.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Zevra Therapeutics, Inc.'s remainder of fiscal year 2024?: Zevra Therapeutics, Inc. (ZVRA) reported remainder of fiscal year 2024 of $396K in Q1 2026.